Mechanism of triptolide in the treatment of gastric cancer with diabetes through JAK2/STAT3 pathway.

Univariate and multivariate Cox analyses revealed a correlation between diabetes and the prognosis of gastric cancer patients (p < 0.05). Using bioinformatics, Serine/threonine-protein kinase pim-1 (PIM1) was identified as the core target gene of triptolide in the treatment of gastric cancer patients with diabetes. Cell Counting Kit-8 (CCK8), cell scratch and plate cloning experiments revealed that triptolide can inhibit the proliferation and migration ability of AGS and HGC-27 cells in a high-glucose environment. Western blot and flow cytometry analysis revealed that triptolide can inhibit PIM1 protein expression, reduce JAK2/STAT3 phosphorylation, and promote apoptosis in AGS and HGC-27 cells under high-glucose conditions. Diabetes is an independent prognostic risk factor for patients with gastric cancer. Triptolide reverses the malignant phenotype of gastric cancer cells induced by high glucose by targeting the PIM1-JAK2/STAT3 signalling axis, providing an experimental basis for the precise treatment of patients with gastric cancer with diabetes.